DGAP-News

ERYTECH PHARMA SA: ERYTECH announces granting of new patent in the United States - Seite 3

treated, even the most fragile ones, representing a market opportunity of
more than EUR 1 billion.

The company is also developing other indications in solid tumors and
certain orphan indications outside oncology. The company is currently
launching a Phase II study in pancreas cancer and is exploring other solid
tumor indications.

ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA(R) in ALL,
AML and pancreas cancer, both in Europe and the USA, and has its own
GMP-approved and operational manufacturing site in Lyon (France), and a
site for clinical production in Philadelphia (USA).

The company has concluded licensing and distribution partnership agreements
for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL
with TEVA in Israel.

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code:
FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. &
Bio and Next Biotech indexes.


Forward-looking information

This document may contain forward-looking statements and estimates with
respect to the financial situation, the results of operations, the
strategy, the project and to the anticipated future performance of ERYTECH
and of the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as,
without limitation, "believes", "anticipates", "expects", "intends",
"plans", "seeks", "estimates", "may", "will" and "continue" and similar
expressions. They include all matters that are not historical facts. Such
statements, forecasts and estimates are based on various assumptions and
assessments of known and unknown risks, uncertainties and other factors,
which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors
that are beyond the Company's control. Therefore, actual results, the
financial condition, performance or achievements of ERYTECH, or industry
results, may turn out to be materially different from any future results,
performance or achievements expressed or implied by such statements,
forecasts and estimates. Documents filed by ERYTECH Pharma with the French
Autorité des Marchés Financiers (www.amf-france.org), also available on our
website (www.erytech.com) describe such risks and uncertainties. Given
these uncertainties, no representations are made as to the accuracy or
fairness of such forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates only speak
as of the date of the publication of this document. ERYTECH disclaims any
obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in the Company's expectations with regard
thereto, or any change in events, conditions or circumstances on which any
such statement, forecast or estimate is based, except to the extent
required by French law.

CONTACTS

ERYTECH                          NewCap



Gil Beyen                        Julien Perez & Emmanuel Huynh

Chairman & CEO                   Investor Relations

Pierre-Olivier Goineau           Nicolas Mérigeau

Vice-President & COO             Press Relations

Tel : [phone]          Tel : [phone]

[e-mail]            [e-mail]

---------------------------------------------------------------------

21.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


292544 21.10.2014